New anesthesia combo aims to keep elderly patients safer during ERCP
NCT ID NCT07584902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at which combination of sedative and painkiller drugs works best to prevent low oxygen levels and low blood pressure in older adults (age 60+) undergoing a procedure called ERCP for bile duct or pancreas problems. About 236 participants will be randomly assigned to receive either propofol or ciprofol as the sedative, and either sufentanil or es-ketamine as the painkiller. The goal is to find the safest anesthesia approach for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY AND PANCREATIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••